Today: 1 May 2026
Browse Category

NYSE:ABT 7 July 2025 - 20 November 2025

Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott will acquire Exact Sciences for $105 per share in cash, valuing the deal at about $23 billion including debt. The boards of both companies approved the transaction, which is set to close in the second quarter of 2026 pending shareholder and regulatory approval. Exact Sciences will become a subsidiary, expanding Abbott’s diagnostics revenue and portfolio. The offer represents a 21–22% premium to Exact’s last closing price.
20 November 2025
··
Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Abbott Nears Takeover of Exact Sciences, Sending Cancer Test Maker’s Stock Soaring on November 19, 2025

Abbott Laboratories is in advanced talks to acquire Exact Sciences, sources told Bloomberg on Wednesday, in what would be Abbott’s largest deal since 2016. Exact Sciences shares surged up to 29% intraday, reaching a market value near $16 billion, while Abbott stock fell around 3%. No official comments have been made by either company.
19 November 2025
···
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 20.10.2025

Fed Chair Jerome Powell signaled the central bank may soon pause its balance-sheet runoff, hinting at an end to quantitative tightening. The move could ease monetary conditions and support stocks, though risks remain if earnings weaken. AbbVie and Abbott Laboratories continue to deliver steady dividend growth, appealing to long-term income investors. Walmart’s new OpenAI partnership and AI-driven features have lifted its shares despite sector headwinds.
20 October 2025
···
Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

ABT shares closed at $128 on Oct. 15, down 3.5% for the day and about 2% for the week. Abbott reported Q3 revenue of $11.37 billion, up 6.9% year-over-year but slightly below estimates; adjusted EPS matched forecasts at $1.30. Medical Devices drove growth, while Diagnostics fell 6.6%. Investors sold off the stock after in-line results, with analysts maintaining a Hold rating and a $143.50 median price target.
15 October 2025
··
Global Wearable Health Tech News – June and July 2025

Global Wearable Health Tech News – June and July 2025

Biobeat’s cuffless vital-sign patch received FDA clearance and CE marking for remote hospital monitoring. PharmaSens and SiBionics unveiled the niia™ signature patch, combining a continuous glucose monitor and insulin pump, at ADA 2025. Fasikl’s Felix NeuroAI Wristband became the first FDA-cleared neuromodulation wearable for essential tremor. U.S. HHS Secretary RFK Jr. launched the MAHA initiative for nationwide wearable adoption.
7 July 2025
···
1 2 3

Stock Market Today

  • Cardano (ADA) Prospects: Governance Focus and Potential for Millionaire Returns
    April 30, 2026, 10:39 PM EDT. Cardano (ADA), a governance-focused cryptocurrency launched in 2017 by Ethereum co-founder Charles Hoskinson, once soared to $3.10 but now trades near $0.25. It uses an energy-efficient proof-of-stake blockchain, Ouroboros, enabling faster transaction speeds than Ethereum and requiring rigorous peer reviews for projects to enhance security and scalability. Despite this, its developer community remains small compared to Ethereum's. Cardano's unique governance approach and new features like the Midnight sidechain could attract regulated industries. However, to turn $10,000 into $1 million again, ADA's price must rise 100-fold to $25, pushing its market cap beyond Ethereum but below Bitcoin's. The path to such growth faces significant challenges amid market competition and adoption hurdles.

Latest article

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Nvidia Stock Falls as Google and Amazon AI Chip Push Tests the AI Trade

Nvidia Stock Falls as Google and Amazon AI Chip Push Tests the AI Trade

30 April 2026
Nvidia shares dropped 4.6% to $199.57 Thursday as investors reacted to Alphabet and Amazon expanding sales of their own AI chips. Alphabet reported Google Cloud revenue up 63% and began selling TPU chips directly to customers. AMD and Broadcom shares rose 5.1% and 3.0%, respectively. Amazon said its Trainium chip line secured $225 billion in revenue commitments.
Go toTop